Log in

NASDAQ:UTHRUnited Therapeutics Stock Price, Forecast & News

$117.95
+2.95 (+2.57 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$113.90
Now: $117.95
$118.19
50-Day Range
$95.87
MA: $109.76
$120.18
52-Week Range
$74.31
Now: $117.95
$124.78
Volume541,895 shs
Average Volume611,350 shs
Market Capitalization$5.19 billion
P/E Ratio9.84
Dividend YieldN/A
Beta0.86
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. United Therapeutics Corporation has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin in the United States, the United Kingdom, Canada, France, Germany, Italy, and Japan; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop SM04646, a phase I development-stage Wnt pathway inhibitor for treating idiopathic pulmonary fibrosis. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Read More
United Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.45 billion
Book Value$66.99 per share

Profitability

Net Income$-104,500,000.00

Miscellaneous

Employees860
Market Cap$5.19 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

How has United Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

United Therapeutics' stock was trading at $93.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, UTHR shares have increased by 25.5% and is now trading at $117.95. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of United Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for United Therapeutics.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for United Therapeutics.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings results on Wednesday, April, 29th. The biotechnology company reported $3.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.43 by $0.69. The biotechnology company earned $356.30 million during the quarter, compared to analyst estimates of $343.68 million. United Therapeutics had a net margin of 36.59% and a return on equity of 19.19%. The firm's revenue for the quarter was down 1.7% compared to the same quarter last year. During the same quarter last year, the company posted $3.58 earnings per share. View United Therapeutics' earnings history.

What price target have analysts set for UTHR?

8 brokers have issued twelve-month price targets for United Therapeutics' stock. Their forecasts range from $80.00 to $243.00. On average, they anticipate United Therapeutics' share price to reach $127.88 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price. View analysts' price targets for United Therapeutics.

Has United Therapeutics been receiving favorable news coverage?

News coverage about UTHR stock has trended very positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. United Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutUnited Therapeutics.

Are investors shorting United Therapeutics?

United Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,560,000 shares, an increase of 16.3% from the April 30th total of 3,060,000 shares. Based on an average trading volume of 694,200 shares, the days-to-cover ratio is presently 5.1 days. Approximately 8.4% of the company's stock are sold short. View United Therapeutics' Current Options Chain.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Celgene (CELG), NVIDIA (NVDA), Applied Materials (AMAT), General Electric (GE), Johnson & Johnson (JNJ), Netflix (NFLX) and Exxon Mobil (XOM).

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 64)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 47)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 51)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.16%), State Street Corp (4.35%), AQR Capital Management LLC (1.99%), Acadian Asset Management LLC (1.78%), Nuveen Asset Management LLC (1.76%) and APG Asset Management N.V. (1.75%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View institutional ownership trends for United Therapeutics.

Which institutional investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Morgan Stanley, AJO LP, Squarepoint Ops LLC, Prosight Management LP, Principal Financial Group Inc., and BNP Paribas Arbitrage SA. Company insiders that have sold United Therapeutics company stock in the last year include Martine A Rothblatt, Raymond Dwek, Richard Giltner, and Tommy G Thompson. View insider buying and selling activity for United Therapeutics.

Which institutional investors are buying United Therapeutics stock?

UTHR stock was bought by a variety of institutional investors in the last quarter, including APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Nuveen Asset Management LLC, Tang Capital Management LLC, AQR Capital Management LLC, Emerald Advisers LLC, and Portolan Capital Management LLC. View insider buying and selling activity for United Therapeutics.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $117.95.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $5.19 billion and generates $1.45 billion in revenue each year. The biotechnology company earns $-104,500,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. United Therapeutics employs 860 workers across the globe.

What is United Therapeutics' official website?

The official website for United Therapeutics is www.unither.com.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.